THE API POWDER DIARIES

“The present problem has uncovered some structural weaknesses while in the EU’s medicines supply chain and also a superior dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides mentioned. She advisable that supply chain concerns be tackled within an EU pharmaceutical tactic expected being released by